Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Cost effectiveness of treatments for wet age-related macular degeneration.

Mitchell P, Annemans L, White R, Gallagher M, Thomas S.

Pharmacoeconomics. 2011 Feb;29(2):107-31. doi: 10.2165/11585520-000000000-00000. Review.

PMID:
21244102
[PubMed - indexed for MEDLINE]
2.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

PMID:
18462575
[PubMed - indexed for MEDLINE]
Free Article
3.

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S.

Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.

PMID:
18035208
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.

Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.

Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. doi: 10.1007/s00417-009-1156-9. Epub 2009 Aug 11.

PMID:
19669678
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.

Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.

Clin Ther. 2012 Feb;34(2):446-56. doi: 10.1016/j.clinthera.2012.01.005. Epub 2012 Jan 30.

PMID:
22289279
[PubMed - indexed for MEDLINE]
6.

[Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].

Yanagi Y, Aihara Y, Fukuda T, Hashimoto H.

Nihon Ganka Gakkai Zasshi. 2011 Sep;115(9):825-31. Japanese.

PMID:
22073599
[PubMed - indexed for MEDLINE]
7.

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.

Vedula SS, Krzystolik MG.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005139. doi: 10.1002/14651858.CD005139.pub2. Review.

PMID:
18425911
[PubMed - indexed for MEDLINE]
8.

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.

PMID:
17887807
[PubMed - indexed for MEDLINE]
9.

A cost-effectiveness analysis of three treatments for age-related macular degeneration.

Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.

Retina. 2010 Feb;30(2):212-21. doi: 10.1097/IAE.0b013e3181babd8e.

PMID:
19940805
[PubMed - indexed for MEDLINE]
10.

A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.

Wickens J, Blinder KJ.

Drug Saf. 2006;29(3):189-99. Review.

PMID:
16524319
[PubMed - indexed for MEDLINE]
11.

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51. doi: 10.1016/j.clinthera.2008.12.025.

PMID:
19167602
[PubMed - indexed for MEDLINE]
12.

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.

Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

Ophthalmology. 2007 Jun;114(6):1170-8. Epub 2007 Feb 23.

PMID:
17320964
[PubMed - indexed for MEDLINE]
13.

Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?

Virgili G, Novielli N, Menchini F, Murro V, Giacomelli G.

Curr Drug Targets. 2011 Feb;12(2):212-20. Review.

PMID:
20887240
[PubMed - indexed for MEDLINE]
14.
15.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

PMID:
18513468
[PubMed - indexed for MEDLINE]
Free Article
16.

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Takeda AL, Colquitt J, Clegg AJ, Jones J.

Br J Ophthalmol. 2007 Sep;91(9):1177-82. Epub 2007 May 2. Review.

PMID:
17475698
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.

Studnička J, Říhová B, Rencová E, Rozsíval P, Dubská Z, Chrapek O, Kolář P, Kandrnal V, Demlová R, Pitrová Š, Řehák J.

Ophthalmologica. 2013;230(1):34-42. doi: 10.1159/000350802. Epub 2013 Jun 7.

PMID:
23751929
[PubMed - indexed for MEDLINE]
18.

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.

Ophthalmology. 2001 Nov;108(11):2051-9.

PMID:
11713079
[PubMed - indexed for MEDLINE]
19.

Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.

Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, Semeraro F.

Curr Drug Targets. 2011 Feb;12(2):149-72. Review.

PMID:
20887246
[PubMed - indexed for MEDLINE]
20.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17.

PMID:
18179676
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk